Enhancing efficiency and quality of statistical estimation of immunogenicity assay cut points through standardization and automation.

Biotherapeutics can elicit immune responses, which can alter the exposure, safety, and efficacy of the therapeutics. A well-designed and robust bioanalytical method is critical for the detection and characterization of relevant anti-drug antibody (ADA) and the success of an immunogenicity study. As a fundamental criterion in immunogenicity testing, assay cut points need to be statistically established with a risk-based approach to reduce subjectivity. This manuscript describes the development of a validated, web-based, multi-tier customized assay statistical tool (CAST) for assessing cut points of ADA assays. The tool provides an intuitive web interface that allows users to import experimental data generated from a standardized experimental design, select the assay factors, run the standardized analysis algorithms, and generate tables, figures, and listings (TFL). It allows bioanalytical scientists to perform complex statistical analysis at a click of the button to produce reliable assay parameters in support of immunogenicity studies.

[1]  S. Richards,et al.  Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations , 2014, The AAPS Journal.

[2]  Viswanath Devanarayan,et al.  Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. , 2008, Journal of pharmaceutical and biomedical analysis.

[3]  David Hoffman,et al.  Statistical considerations for calculation of immunogenicity screening assay cut points. , 2011, Journal of immunological methods.

[4]  Harry Yang,et al.  Statistical methods and tool for cut point analysis in immunogenicity assays. , 2013, Journal of immunological methods.

[5]  Boris Gorovits,et al.  Theoretical Considerations and Practical Approaches to Address the Effect of Anti-drug Antibody (ADA) on Quantification of Biotherapeutics in Circulation , 2013, The AAPS Journal.

[6]  Mark Ma,et al.  Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment , 2013, The AAPS Journal.

[7]  Troy E. Barger,et al.  Comparing Exponentially Weighted Moving Average and Run Rules in Process Control of Semiquantitative Immunogenicity Immunoassays , 2009, The AAPS Journal.

[8]  P. Vicini,et al.  A Mathematical Model of the Effect of Immunogenicity on Therapeutic Protein Pharmacokinetics , 2013, The AAPS Journal.

[9]  G. Oehlert.  A note on the delta method , 1992 .

[10]  Marian Kelley,et al.  Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. , 2007, Journal of immunological methods.

[11]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[12]  Lakshmi Amaravadi,et al.  A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution. , 2010, Journal of immunological methods.

[13]  Michael Hale,et al.  A Step-wise Approach for Transfer of Immunogenicity Assays during Clinical Drug Development , 2009, The AAPS Journal.

[14]  K. Sonehara,et al.  A White Paper—Consensus and Recommendations of a Global Harmonization Team on Assessing the Impact of Immunogenicity on Pharmacokinetic Measurements , 2014, The AAPS Journal.

[15]  Melody Sauerborn,et al.  Is the tiered immunogenicity testing of biologics the adequate approach in preclinical development? , 2013, Bioanalysis.

[16]  Daniel Sikkema,et al.  Complexities of Clinical Assay Development and Optimization Prior to First-in-Man Immunization Trials – A Description of Immunogenicity Assay Development for the Testing of Samples from a Phase 1 Alzheimer's Vaccine Trial , 2008, Journal of immunoassay & immunochemistry.

[17]  Francesca Civoli,et al.  Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum. , 2012, Journal of immunological methods.

[18]  R Seitz,et al.  Taking immunogenicity assessment of therapeutic proteins to the next level. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[19]  Vibha Jawa,et al.  Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy , 2012, The AAPS Journal.

[20]  Rafael Ponce,et al.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. , 2009, Regulatory toxicology and pharmacology : RTP.

[21]  T. Jaki,et al.  A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. , 2011, Journal of pharmaceutical and biomedical analysis.

[22]  Satterthwaite Fe.  An approximate distribution of estimates of variance components. , 1946 .

[23]  Chad Ray,et al.  Identification and inhibition of drug target interference in immunogenicity assays. , 2010, Journal of immunological methods.